Can BRIGHT restore the glow of bivalirudin?

JAMA - Journal of the American Medical Association

Volumn 313, Issue 13, 2015, Pages 1323-1324

  Cavender, Matthew A ^a   Faxon, David P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; ANTITHROMBIN; FIBRINOLYTIC AGENT; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; TIROFIBAN; TYROSINE;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; BLEEDING; CARDIOLOGIST; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DEATH; DRUG EFFICACY; EDITORIAL; GENDER; HUMAN; ISCHEMIA; KIDNEY DYSFUNCTION; MORTALITY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOSIS; TREATMENT DURATION; VASCULAR ACCESS; ANALOGS AND DERIVATIVES; FEMALE; MALE; MYOCARDIAL INFARCTION;

ANTITHROMBINS; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDINS; HUMANS; MALE; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; RECOMBINANT PROTEINS; TYROSINE;

EID: 84927556031     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.2345     Document Type: Editorial

References (14)

1. Lincoff AM, Bittl JA, Harrington RA, et al; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289(7):853-863.
2. Kastrati A, Neumann FJ, Mehilli J, et al; ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359(7): 688-696.
3. Stone GW, McLaurin BT, Cox DA, et al; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355(21): 2203-2216.
4. Kastrati A, Neumann FJ, Schulz S, et al; ISAR-REACT 4 Trial Investigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med. 2011;365(21): 1980-1989.
5. Stone GW,Witzenbichler B, Guagliumi G, et al; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acutemyocardial infarction. N Engl J Med. 2008;358(21):2218-2230.
6. Steg PG, van 't Hof A, Hamm CW, et al; EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl JMed. 2013;369(23):2207-2217.
7. Stone GW, Bertrand ME, Moses JW, et al; ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA. 2007;297(6):591-602.
8. Giugliano RP, White JA, Bode C, et al; EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009;360(21):2176-2190.
9. Windecker S, Kolh P, Alfonso F, et al; Authors/Task Force members. 2014 ESC/EACTS Guidelines onmyocardial revascularization: the Task Force onMyocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541-2619.
10. Shahzad A, Kemp I, Mars C, et al; HEAT-PPCI trial investigators. Unfractionated Heparin Versus Bivalirudin in Primary Percutaneous Coronary Intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014; 384(9957):1849-1858.
11. Han Y, Guo J, Zheng Y, et al; the BRIGHT Investigators. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acutemyocardial infarction: the BRIGHT randomized clinical trial. JAMA. doi:10.1001/jama.2015.2323.
12. Bhatt DL, Cavender MA. Are all clinical trial sites created equal? J AmColl Cardiol. 2013;61(5):580-581.
13. Cavender MA, SabatineMS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: ameta-analysis of randomised controlled trials. Lancet. 2014;384 (9943):599-606.
14. Bangalore S, Toklu B, Kotwal A, et al. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: ameta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. BMJ. 2014;349:g6419.